![News Logos7 News Logos7](https://usbiologic.com/wp-content/uploads/2021/12/News-Logos7-300x188.jpg)
Memphis-based US Biologic receives funding to develop orally administered flu vaccine
A Memphis-based biotech company announced in early August a partnership with a federal agency to work on a temperature stable, oral vaccine against two strains of the influenza virus. US Biologic, known for its proprietary oral-delivery platform OrisBio, produces oral vaccines and therapeutics, which are currently being used in animals to prevent zoonotic diseases. The company describes its platform as “safe, efficacious, and cost-effective for other infectious diseases with pandemic potential.”